Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”
Clinical and Molecular Hepatology. 2023;29(3):820-820 
Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”
Clinical and Molecular Hepatology. 2023;29(3):812-812
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?
Clinical and Molecular Hepatology. 2023;29(2):367-370
Erratum to ‘Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?’ [Clin Mol Hepatol 2023;29:367-370]
Clinical and Molecular Hepatology. 2023;29(3):828-829
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
Clinical and Molecular Hepatology. 2023;29(2):513-515
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”
Clinical and Molecular Hepatology. 2023;29(2):510-512
Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune tolerant phase
Alimentary Pharmacology & Therapeutics. 2020;52(6):1093-1093
Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune‐tolerant phase—authors' reply
Alimentary Pharmacology & Therapeutics. 2020;52(6):1094-1095
PRO: Patients With Chronic Hepatitis B in Immune‐Tolerant Phase Should Be Treated
Clinical Liver Disease. 2020;15(1):21-24
Letter: risk of hepatocellular carcinoma in immune‐tolerant phase of chronic hepatitis B—authors’ reply
Alimentary Pharmacology & Therapeutics. 2020;52(5):913-914